Overview

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Status:
Recruiting
Trial end date:
2034-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival
Phase:
Phase 2
Details
Lead Sponsor:
Melanoma Institute Australia
Collaborator:
Bristol-Myers Squibb
Treatments:
Nivolumab
Relatlimab